Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hims & Hers Health and Novo Nordisk announced a collaboration regarding the development of GLP-1 weight-loss drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Novo Nordisk's Wegovy rollout is planned for Germany as GLP-1 therapies shift consumer priorities.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.
- Svetlana Mojsov discussed GLP-1 drug research findings with Luke O'Neill, referencing technology foundations laid in the 1980s.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
Coverage
Newest first; wire copies grouped- financialcontent.comHims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know